THE UK Commission on Human
Medicines (CHM) will set up an
expert working group to review
information on use of alteplase for
ischaemic stroke.
This comes after the CHM
considered evidence available
following the extension of the
treatment window for alteplase
in stroke and concluded that the
data did not change the balance
of benefits outweighing the risks
for the medication’s use and that it
remained an effective medicine for
treating ischaemic stroke.
However it said an expert working
group should be set up, to report
in early 2015 on whether the
evidence had implications on the
risk-benefit ratio.
The TGA said it would consider
the CHM review and any
information from the expert
working group to determine
whether action was required here.
Boehringer Ingelheim said experts
had responded to the original
issues raised in the Lancet, pointing
out inaccuracies, and that all data
had been made available.
CLICK HERE for more.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Aug 14
THE Australian Government has lowered the age of eligibility for its free National Bowel Cancer Screening Program (NBCSP) to 45, unlocking access to the test kits to more than 1.6 million Australians.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.